Clinical trials: Locally Advanced Cervical Cancer, open to volunteers
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved…
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy
- Trial name
- NCT06056336
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guo Xufeng
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is one of the common malignant tumors in the world. More than 60% of HNSCC patients are locally advanced when first diagnosed.
- Trial name
- NCT06814067
- Testing
- Pembrolizumab, Ivonescimab, Surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A single-arm, single-center clinical trial evaluating efficacy (Phase #)
- Trial name
- NCT07550972
- Testing
- A single-arm, single-center clinical trial evaluating efficacy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma
Neoadjuvant Immunochemotherapy for LAOSCC
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally…
- Trial name
- NCT06258811
- Testing
- albumin paclitaxel, cispatin, tislelizumab
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Lai-ping Zhong
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer.
- Trial name
- HCHTOG1903 (NCT04138212)
- Testing
- Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital
Cervical Cancer by FIGO Stage 2018
Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers
Cervical cancer is the fourth most common cancer among women and is mainly linked to infection with high-risk human papillomaviruses (HPV).
- Trial name
- RETHEMCOL (NCT07461142)
- Testing
- radiotherapy with bone marrow contouring
- Volunteers
- 72 people
- Sponsor
- Institut Paoli-Calmettes
Uterine Cervical Neoplasms, Locally Advanced Cervical Carcinoma
PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer
This prospective, multicenter, nonrandomized phase-II-trial investigates in clinical practice the differences between intensity modulated proton therapy (IMPT) and standard intensity-modulated radiation therapy (IMRT) or…
- Trial name
- PROTECT (NCT05406856)
- Testing
- External beam radiation therapy: IMRT/VMAT, External beam radiation therapy: IMPT, Cisplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Leiden University Medical Center
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC)
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a randomized controlled, phase II clinical study designed to explore the efficacy and safety of nimotuzumab combined with immunotherapy and chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
- Trial name
- NCT07601737
- Testing
- Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Head and Neck Cancer
Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC
This is a single-center, single-arm phase II clinical study designed to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab combined with cetuximab in patients with locally advanced resectable oral squamous cell…
- Trial name
- NCT07882888
- Testing
- iparomlimab and tuvonralimab combined with cetuximab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Nuclear Medicine, Oncology
Application of 18F-FDG PET/MRI for Initial Staging in Locally Advanced Nasopharyngeal Carcinoma
This single-center prospective observational study aims to evaluate the feasibility, cost-effectiveness, and clinical value of positron emission tomography/magnetic resonance imaging (PET/MRI) for initial staging in patients with…
- Trial name
- NCT06947759
- Testing
- PET/MRI
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Taichung Veterans General Hospital
Cutaneous Squamous Cell Carcinoma
Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck
The goal of this clinical trial is to learn if the combination of the drug cemiplimab along with a short course of radiation therapy called Quad Shot can be successfully given in several rounds to elderly or frail patients with…
- Trial name
- NCT07869823
- Testing
- Cemiplimab, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Squamous Cell Carcinoma
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
We plan to conduct a single-center,prospective, Open Label, Randomized Controlled, Phase II Clinical Study of the Combination of Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced…
- Trial name
- NCT07312578
- Testing
- Nimotuzumab, camrelizumab, Albumin paclitaxel
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University
Esophageal Cancer
Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
This study is a prospective, single center, open label, single arm clinical study. Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with pathological diagnosis of squamous cell…
- Trial name
- NCT06304350
- Testing
- Combination of pembrolizumab and platinum containing dual drugs
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tongji University
Nasopharyngeal Carcinoma (NPC)
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
This multicenter, open-label, randomized Phase III trial evaluates intensity-modulated proton therapy (IMPT) versus intensity-modulated photon radiotherapy (IMRT) in patients with newly diagnosed, high-risk, locoregionally…
- Trial name
- NCT07340515
- Testing
- Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT), Cisplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Man Hu
Esophageal Cancer
Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW
Radiation and chemotherapy can shrink the tumor. For certain types of cancer, immunotherapy is added to further reduce the tumor size.
- Trial name
- GLOW (NCT07196384)
- Testing
- Spectroscopy system, Nivolumab-800CW, Durvalumab-680LT
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen